Latest Partnerships News

The a2 Milk Company has reported robust first-half FY25 results, boosting full-year guidance and declaring its inaugural dividend, underscoring confidence in its growth trajectory.

Contact Energy reported a 12% rise in EBITDAF to $404 million for 1H25, driven by new geothermal assets and strategic contracts, while net profit fell 7% due to market volatility and acquisition costs.

Osteopore Limited has drawn down A$2 million from the first tranche of its redeemable convertible notes, using the proceeds to repay existing loans and support ongoing business activities.

Bulletin Resources has received the final $0.8 million payment from Ramelius Resources for the partial sale of tenure at its Lake Rebecca Gold Project, completing a transaction that has injected nearly $4.8 million into the company since 2021.

Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.

Patriot Battery Metals reported a Q3 net loss of $2.23 million and a nine-month loss of $5.60 million, reflecting heavy investment in its flagship Shaakichiuwaanaan lithium project. A strategic $69 million private placement with Volkswagen post-quarter end underscores growing industry confidence.

Macarthur Minerals Limited reported a comprehensive loss of AUD 252,771 for Q4 2024, marking a sharp reversal from the prior year's profit. The company is navigating reduced exploration spending and strategic asset sales while facing ongoing funding challenges.

Scorpion Minerals Limited has had its trading suspension lifted following an announcement about a potential joint venture and capital raising, signaling renewed market activity.

E79 Gold Mines has entered a strategic earn-in and joint venture agreement with Scorpion Minerals over the Jungar Flats Project, enabling E79 to reduce expenditure while focusing on promising gold and copper-gold projects elsewhere.

Wellnex Life Limited has locked in A$9 million in conditional commitments to support its proposed dual listing on the London Stock Exchange’s AIM market, alongside launching a 1:1 entitlement offer for existing shareholders.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.

Artrya Limited has secured A$15 million through a two-tranche placement aimed at accelerating regulatory approvals and commercial rollout of its Salix® coronary artery disease diagnostic software in the US.